The Wall Street Journal (online registration required): The U.S. Food and Drug Administration ordered 23andMe Inc. to stop marketing its $99 mail-order genetic test, citing the risk that false results could cause consumers to undergo unnecessary health procedures including breast surgery.
The FDA said in a Nov. 22 warning letter to 23andMe Chief Executive Anne Wojcicki that the company doesn't have the proper marketing clearance to sell the DNA testing kit, and 23andMe hasn't sufficiently worked with the agency to secure such approval. The FDA said it hasn't heard from the...
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now